Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Newly Discovered Clinical Recurrence Predictor for High-risk Hormone Receptor-positive Breast Cancer: a Real Word Study

NCT04476485 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04476485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Newly Discovered Clinical Recurrence Predictor for High-risk Hormone Receptor-positive Breast Cancer: a Real Word Study
Lead sponsor
Shengjing Hospital
Phase
Observational
Overall status
Recruiting
Start date
July 19, 2021
Completion date
December 31, 2026
Enrollment
1,000 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer